The American Urological Association (AUA) released its Incontinence after Prostate Treatment Guideline in June 2024 which we will be diving into in honor of National Prostate Cancer Awareness Month 2024. This updated guideline is designed to assist clinicians in making well-informed care decisions for patients experiencing incontinence following treatment for localized prostate cancer and benign prostatic hyperplasia (BPH). It explores the various treatment options available for patients with Incontinence after Prostate Treatment (IPT).

Patients dealing with IPT encounter significant challenges, including emotional and financial burdens, as well as difficulties reintegrating into society, impacting relationships and placing strain on both patients and their families. This condition has garnered attention due to the widespread use of prostate cancer surgery and the availability of men’s incontinence products on the market.

Following the 5-year mark since the release of the previous IPT guideline, it is important to highlight key changes and takeaways. While this list does not encompass all changes, it serves to provide a glimpse into the updates. For a comprehensive list of new recommendations, please refer to the full text guidelines located below:

Key Takeaways from the 2024 Guidelines Compared to 2019:

Updated Evidence Base:

The 2024 guideline has been enriched with new evidence gathered from studies published between 2019 and 2023. This includes the incorporation of 17 new studies that met the inclusion criteria.

Refined Recommendations:

The recommendations have been fine-tuned to align with the latest research findings and clinical practices. This includes providing more specific guidance on managing incontinence following prostate treatment.

New Statement based on Literature in the 2024 Guideline:

A new statement is included to encourage clinicians to counsel patients on the risk factors associated with artificial urinary sphincter erosion. 

New Expert Opinion Statement:

The Panel has developed a new expert opinion statement with supporting text. After removing an eroded device, clinicians may address artificial urinary sphincter urethral cuff erosion intra-operatively using a urethral catheter alone, in situ urethroplasty, or anastomotic urethroplasty. 

Pre-Treatment Counseling:

There is an increased emphasis on pre-treatment counseling in the 2024 guideline. Clinicians are advised to educate patients on all known factors that could impact continence before undergoing prostate cancer treatment.

Patient-Centered Care:

The 2024 guideline prioritize patient-centered care, highlighting the significance of personalized treatment plans and shared decision-making.

Expanded Treatment Options:

The guidelines now feature a more comprehensive discussion on treatment options, including newer therapies and interventions that have emerged since 2019.

Decreased Incidence of Incontinence:

The updated guideline anticipates a reduction in the incidence of incontinence due to advancements in prostate treatments.

We appreciate your participation in our Guidelines Spotlight on Incontinence after Prostate Treatment. These evolving guidelines aim to improve both patient care and outcomes for men with this condition. We value your thoughts and feedback and look forward to our next spotlight event.

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2024 Guideline Central, all rights reserved.